These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 22751604)

  • 1. Should we consider tumor necrosis factor as the only target in spondyloarthritides?
    Ferraccioli G; Gremese E
    J Rheumatol Suppl; 2012 Jul; 89():94-6. PubMed ID: 22751604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Th17 and interleukin 23 in the pathogenesis of psoriatic arthritis and spondyloarthritis.
    Cauli A; Mathieu A
    J Rheumatol Suppl; 2012 Jul; 89():15-8. PubMed ID: 22751583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current concepts in psoriatic arthritis: pathogenesis and management.
    de Vlam K; Gottlieb AB; Mease PJ
    Acta Derm Venereol; 2014 Nov; 94(6):627-34. PubMed ID: 24573106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction.
    Zwerina J; Hayer S; Tohidast-Akrad M; Bergmeister H; Redlich K; Feige U; Dunstan C; Kollias G; Steiner G; Smolen J; Schett G
    Arthritis Rheum; 2004 Jan; 50(1):277-90. PubMed ID: 14730626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TNF blockade requires 1,25(OH)2D3 to control human Th17-mediated synovial inflammation.
    van Hamburg JP; Asmawidjaja PS; Davelaar N; Mus AM; Cornelissen F; van Leeuwen JP; Hazes JM; Dolhain RJ; Bakx PA; Colin EM; Lubberts E
    Ann Rheum Dis; 2012 Apr; 71(4):606-12. PubMed ID: 22219138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy.
    Herman S; Krönke G; Schett G
    Trends Mol Med; 2008 Jun; 14(6):245-53. PubMed ID: 18468489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of spondyloarthropathy: the potential for agents other than TNF inhibitors.
    Her M; Kavanaugh A
    Curr Opin Rheumatol; 2013 Jul; 25(4):455-9. PubMed ID: 23680779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells.
    Ma HL; Napierata L; Stedman N; Benoit S; Collins M; Nickerson-Nutter C; Young DA
    Arthritis Rheum; 2010 Feb; 62(2):430-40. PubMed ID: 20112373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remission of collagen-induced arthritis is associated with high levels of transforming growth factor-beta expression in the joint.
    Marinova-Mutafchieva L; Gabay C; Funa K; Williams RO
    Clin Exp Immunol; 2006 Nov; 146(2):287-93. PubMed ID: 17034581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
    Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
    Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomic issues in psoriatic arthritis.
    Olivieri I; D'Angelo S; Palazzi C; Padula A; Lubrano E; Mantovani LG
    J Rheumatol Suppl; 2012 Jul; 89():103-5. PubMed ID: 22751607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab.
    Brandt J; Haibel H; Reddig J; Sieper J; Braun J
    J Rheumatol; 2002 Jan; 29(1):118-22. PubMed ID: 11824947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor necrosis factor and anti-tumor necrosis factor therapies.
    Keystone EC; Ware CF
    J Rheumatol Suppl; 2010 May; 85():27-39. PubMed ID: 20436163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression?
    Soczynska JK; Kennedy SH; Goldstein BI; Lachowski A; Woldeyohannes HO; McIntyre RS
    Neurotoxicology; 2009 Jul; 30(4):497-521. PubMed ID: 19477018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion.
    Lubberts E; Koenders MI; Oppers-Walgreen B; van den Bersselaar L; Coenen-de Roo CJ; Joosten LA; van den Berg WB
    Arthritis Rheum; 2004 Feb; 50(2):650-9. PubMed ID: 14872510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model.
    Chabaud M; Miossec P
    Arthritis Rheum; 2001 Jun; 44(6):1293-303. PubMed ID: 11407688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis.
    Eljaafari A; Tartelin ML; Aissaoui H; Chevrel G; Osta B; Lavocat F; Miossec P
    Arthritis Rheum; 2012 Jul; 64(7):2147-57. PubMed ID: 22275154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholecystokinin octapeptide significantly suppresses collagen-induced arthritis in mice by inhibiting Th17 polarization primed by dendritic cells.
    Li Q; Han D; Cong B; Shan B; Zhang J; Chen H; Ma C; Liyanage SS
    Cell Immunol; 2011; 272(1):53-60. PubMed ID: 22004797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of interleukin-17A protects against coxsackievirus B3-induced myocarditis by increasing COX-2/PGE2 production in the heart.
    Xie Y; Chen R; Zhang X; Yu Y; Yang Y; Zou Y; Ge J; Chen H; Garzino-Demo A
    FEMS Immunol Med Microbiol; 2012 Apr; 64(3):343-51. PubMed ID: 22141571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.